Firms To Be Held More Accountable For Completing Postmarket Studies – FDA

FDA plans to shift the tracking of postmarket studies from the Office of Device Evaluation to the Office of Surveillance & Biometrics by year-end to enable ODE to better meet MDUFMA goals